Loading cancer entity…
Loading cancer entity…
Clinical trials
8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,291)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06616389 | Study of ODX (OsteoDex) in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 12 | DexTech Medical ABINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07021495 |
| SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)(SKINERGY) |
| recruiting |
| — |
| 840 |
| Leiden University Medical CenterOTHER |
| 1 |
| Aug 19, 2025 |
| clinicaltrials |
| NCT07078500 | Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06497738 | A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma | recruiting | — | 112 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | recruiting | N/A | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05565807 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05913804 | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | active not recruiting | Phase 1 | 34 | AbbVieINDUSTRY | 4 | Aug 14, 2025 | clinicaltrials |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 0 | Aug 14, 2025 | clinicaltrials |
| NCT06978088 | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | recruiting | Phase 2 | 34 | Zulfa OmerOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04892667 | Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG(DETECT) | active not recruiting | N/A | 128 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05583071 | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL(MTR²) | recruiting | Phase 2 | 20 | University of CologneOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)(BV mini CHP) | active not recruiting | Phase 2 | 24 | Patrick ReaganOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06530550 | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 51 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07117305 | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 1 / Phase 2 | 38 | Zhengzhou UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07114432 | RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma | not yet recruiting | Phase 1 | 19 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT04099966 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | recruiting | Phase 2 | 20 | Mitchell CairoOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07111884 | GMMG Multiple Myeloma Registry | recruiting | — | 999 | Prof. Dr. Hartmut GoldschmidtOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06365060 | Screening for AL Amyloidosis in Smoldering Multiple Myeloma | recruiting | — | 400 | Tufts Medical CenterOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106671 | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106684 | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia(CAREMM-004) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106710 | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma(CAREMM-005) | recruiting | Phase 2 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106723 | Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106736 | MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma(MAGIC-TIEMM) | recruiting | Phase 2 | 60 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | active not recruiting | Phase 2 | 120 | AbbVieINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05841550 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06793449 | BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma(CAREMM-006) | recruiting | Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06880393 | BCMA CAR-T for Dynamic High-risk Multiple Myeloma(CAREMM-003) | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06762769 | Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma(MODIFY) | recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06838832 | Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 84 | Cancer Research UKOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07087964 | Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients(IMMPROVED) | recruiting | — | 120 | Universiteit AntwerpenOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088783 | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients(OCARE-MM) | active not recruiting | N/A | 60 | OzlemOTHER | 1 | Jul 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 19, 2025source: clinicaltrials